Autologous Cell Therapy Companies

December 2023:

AtCure Pharmaceuticals partners with Cytovia on Phase IIB for APL1301 for advanced solid tumor. This signifies progress in broadening autologous cell therapy applications for cancer.

November 2023:

Fate Therapeutics and Takeda Pharmaceuticals International collaborate on development and commercialization of CAR T-cell therapy for CD30+ lymphomas. This highlights the continued focus on expanding CAR T-cell therapy beyond B-cell malignances.

Jan 2024:

Legend Biotech receives China National Medical Products Administration (NMPA) approval for LCAR-017 for relapsed/refractory B-cell lymphomas. This signifies the first regulatory approval for CAR T-cell therapy in China.

Dec 2023:

BlueRock Therapeutics releases encouraging Phase I/II data for autologous T-cell therapy for PD-L1 negative non-small cell lung cancer. this marks progress in tackling challenging cancer types with autologous therapies.

Jan 2024:

Report projects autologous cell therapy market to reach $33.1 billion by 2032, fueled by rising demand for personalised treatments. This underscores the market's continued strong growth potential.

Oct 2023:

Thermo Fisher and UCSF unveil new cGMP cell therapy manufacturing facility. This highlights ongoing efforts to overcome manufacturing challenges and expedite therapy development.

• Bristol Myers Squibb (US)


• Bayer AG (Germany)


• Autolus Therapeutics (UK)


• Sangamo Therapeutics (US)


• Holostem Terapie Avanzate S.r.l.(Modena)


• Vericel Corporation (US)


• Opexa Therapeutics (US)


• BrainStorm Cell Therapeutics (US)


• Pharmicell Co., Inc. (South Korea)


• Daiichi Sankyo Co (Japan)., Ltd, among others